Axa’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-79,059
| Closed | -$13.6M | – | 1315 |
|
|
2021
Q3 | $13.6M | Sell |
79,059
-89,946
| -53% | -$11.8M | 0.04% | 409 |
|
|
2021
Q2 | $21.2M | Sell |
169,005
-14,295
| -8% | -$1.8M | 0.06% | 332 |
|
|
2021
Q1 | $24.9M | Sell |
183,300
-47,614
| -21% | -$6.15M | 0.08% | 304 |
|
|
2020
Q4 | $29.5M | Sell |
230,914
-9,743
| -4% | -$1.14M | 0.09% | 243 |
|
|
2020
Q3 | $27.1M | Sell |
240,657
-3,658
| -1% | -$364K | 0.1% | 239 |
|
|
2020
Q2 | $23.3M | Buy |
244,315
+35,530
| +17% | +$3.42M | 0.09% | 240 |
|
|
2020
Q1 | $18.8M | Sell |
208,785
-46,150
| -18% | -$3.59M | 0.09% | 235 |
|
|
2019
Q4 | $13.5M | Sell |
254,935
-111,117
| -30% | -$5.07M | 0.06% | 374 |
|
|
2019
Q3 | $14.5M | Sell |
366,052
-4,903
| -1% | -$213K | 0.06% | 369 |
|
|
2019
Q2 | $15.2M | Buy |
370,955
+70,641
| +24% | +$2.92M | 0.06% | 362 |
|
|
2019
Q1 | $14M | Buy |
300,314
+231,579
| +337% | +$10.2M | 0.05% | 380 |
|
|
2018
Q4 | $2.99M | Buy |
68,735
+29,515
| +75% | +$1.47M | 0.01% | 732 |
|
|
2018
Q3 | $2.25M | Sell |
39,220
-90,835
| -70% | -$4.46M | 0.01% | 853 |
|
|
2018
Q2 | $6.31M | Sell |
130,055
-103,449
| -44% | -$3.77M | 0.02% | 587 |
|
|
2018
Q1 | $9.13M | Sell |
233,504
-35,311
| -13% | -$1.5M | 0.04% | 472 |
|
|
2017
Q4 | $11.4M | Sell |
268,815
-277
| -0.1% | -$10.4K | 0.04% | 426 |
|
|
2017
Q3 | $10M | Sell |
269,092
-54,463
| -17% | -$1.89M | 0.04% | 431 |
|
|
2017
Q2 | $9.83M | Buy |
+323,555
| New | +$9.38M | 0.04% | 429 |
|
Axa's XLRN Position: Q4 2021 in Review
Axa sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 79,059 shares — an estimated $13.6M sold.
Axa first reported a position in XLRN in Q2 2017 and held it in 18 quarters. The position peaked at $29.5M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Axa reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Axa sold 79,059 Acceleron Pharma shares in Q4 2021, an estimated $13.6M.
- Axa first reported a position in Acceleron Pharma in Q2 2017 and held it in 18 quarters.
- Axa's Acceleron Pharma position peaked at $29.5M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Axa's 13F filing for Q4 2021, filed 14 Feb 2022.